Compare Summit Therapeutics Inc (SMMT) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Atlassian Corporation PLC — how do they compare? Summit Therapeutics Inc trades at $17.52 (market cap $13.79B), while Atlassian Corporation PLC trades at $178.15 (market cap $44.66B). The key difference: Atlassian Corporation PLC is far larger — about 3.2× Summit Therapeutics Inc's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | TEAM | |
|---|---|---|
Market Cap | $13.79B | $44.66B |
Sector | Health | Technology |
52-Week High | $26.38 | $194.68 |
52-Week Low | $12.43 | $57.15 |
Enterprise Value | $13.11B | $44.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Atlassian (TEAM) trades at $176.42, down 6.94% on the day, despite strong recent performance with three consecutive quarterly earnings beats. The stock maintains a bullish technical signal with support at $173 and resistance at $182. Revenue growth continues at $5.22B (2025) with improving margins, though the company remains unprofitable with a -0.82% net income margin. Analyst consensus is strongly bullish with 30 buy ratings and a $179.81 price target, while recent news highlights AI integration driving cloud growth.
TEAM presents a growth-oriented investment with significant upside potential from AI adoption and market expansion, but carries risks from persistent losses, premium valuation (P/S 6.98), and insider selling. The path to profitability remains key, with projected net losses narrowing to -$54M in 2026. Investors should weigh strong analyst support against high execution demands in a competitive SaaS landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
